Our recombinant protein platform uses genetic engineering technology to quickly identify potential antigens and modify their genes to improve their immunogenicity and integrate them into appropriate expression systems. In order to meet the needs of different projects for the characteristics of protein itself, subsequent processes and economic benefits, the platform is equipped with a variety of expression systems, including Escherichia coli, CHO cells, Pichia pastoris and insect cells. The recombinant protein platform has the advantages of high expression antigen content, high purity and easy mass production. It can not only achieve high yield, high purity and low cost, but also solve the safety and effectiveness of some traditional vaccines.